1. Scrip
  2. >>New Products

Interview: Measured Launch, Long Future For Gilead CAR-T In Europe

 
• By Eleanor Malone

Positive recommendations for the approval of CAR-T therapies Yescarta and Kymriah were delivered in Europe in June. Michael Elliott, Gilead Sciences' VP for medical affairs in Europe, spoke to Scrip about the Yescarta launch strategy and the long-term future of CAR-T.

Truck
Gilead is preparing for the long road in CAR-T • Source: Shutterstock

Gilead Sciences Inc. and Novartis AG are poised to simultaneously launch Europe's first CAR-T therapies within the next couple of months following the expected approval from the European Commission of Gilead's Yescarta (axicabtagene ciloleucel) and Novartis' Kymriah (tisagenlecleucel). Both therapies received a positive opinion from the European Medicines Agency's drug evaluation committee, the CHMP, on June 29, paving the way for approval in early September. Both are recommended for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), while Yescarta is also recommended for primary mediastinal B-cell lymphoma and Kymriah for B-cell acute lymphoblastic leukemia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: 13 Approvals And 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.